These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinköthe T; Stützer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A J Clin Oncol; 2005 Oct; 23(28):7024-31. PubMed ID: 16145065 [TBL] [Abstract][Full Text] [Related]
25. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952 [TBL] [Abstract][Full Text] [Related]
26. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271 [TBL] [Abstract][Full Text] [Related]
27. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611 [TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab: what is the secret to safe therapy? Elter T; Hallek M; Montillo M Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865 [TBL] [Abstract][Full Text] [Related]
29. The evolving role of alemtuzumab in management of patients with CLL. Faderl S; Coutré S; Byrd JC; Dearden C; Denes A; Dyer MJ; Gregory SA; Gribben JG; Hillmen P; Keating M; Rosen S; Venugopal P; Rai K Leukemia; 2005 Dec; 19(12):2147-52. PubMed ID: 16239912 [TBL] [Abstract][Full Text] [Related]